Blar i St. Olavs hospital på forfatter "Halvorsen, Tarje Onsøien"
-
Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18F-FDG PET/CT in early-stage non-small cell lung cancer
Ottestad, Anine Larsen; Johansen, Håkon; Halvorsen, Tarje Onsøien; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Emdal, Elisabeth Fritzke; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2023)Background The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic ... -
Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC
Stokke, Kristin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning; Saltvedt, Ingvild; Jordhøy, Marit Slaaen; Kirkevold, Øyvind; Killingberg, Kristin Toftaker; Sandvei, Marie Søfteland (Peer reviewed; Journal article, 2022)Background: There is a lack of tools for selecting patients with advanced lung cancer who benefit the most from systemic treatment. Patient-reported physical function (PRPF) has been identified as a prognostic factor in ... -
Associations between muscle measures, survival and toxicity in patients with limited disease small cell lung cancer receiving concurrent chemoradiotherapy
Halvorsen, Tarje Onsøien; Valan, Christine Damgaard; Jordhøy, Marit Slaaen; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Background Standard treatment for patients with limited stage small cell lung cancer (LS SCLC) is concurrent platinum– etoposide chemotherapy and thoracic radiotherapy (TRT). Up to 30% of patients are cured, but severe ... -
Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients
Grønberg, Bjørn Henning; Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Sjøblom, Bjørg; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2019)Introduction Several studies show that low skeletal muscle index (SMI) and low skeletal muscle density (SMD) are negative prognostic factors and associated with more toxicity from systemic therapy in cancer patients. ... -
Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer
Ottestad, Anine Larsen; Hong, Yan Dai; Halvorsen, Tarje Onsøien; Emdal, Elisabeth Fritzke; Wahl, Sissel Gyrid Freim; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)Introduction: Studies have indicated that detection of mutated KRAS or EGFR in circulating tumor DNA (ctDNA) from pre-treatment plasma samples is a negative prognostic factor for non-small cell lung cancer (NSCLC) pa-tients. ... -
Changes in muscle measures during chemoradiotherapy in patients with limited stage small cell lung cancer
Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Jordhøy, Marit Slaaen; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Background: Concurrent chemoradiotherapy is the recommended treatment for limited stage small cell lung cancer. Severe side‐effects, which might cause loss of muscle mass, are frequent. Low skeletal muscle index (SMI) and ... -
Fragmentation assessment of FFPE DNA helps in evaluating NGS library complexity and interpretation of NGS results
Ottestad, Anine Larsen; Emdal, Elisabeth Fritzke; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Dai, Hong Yan (Journal article; Peer reviewed, 2022) -
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; HORNSLIEN, KJERSTI; Madebo, Tesfaye; Langer, Seppo W.; Schytte, Tine; Risum, Signe; Tsakonas, Georgios; Nyman, Jan; Engleson, Jens; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2022)Objectives In a randomized phase II trial, twice daily (BID) thoracic radiotherapy (TRT) of 60 Gy/40 fractions improved survival compared with 45 Gy/30 fractions in limited stage small-cell lung cancer (LS SCLC). Notably, ... -
The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study
Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Berg, Thomas; Halvorsen, Tarje Onsøien; Ottestad, Anine Larsen; Lund-Iversen, Marius; Brustugun, Odd; Førde, Dagny; Paulsen, Erna-Elise; Donnem, Tom; Andersen, Sigve; Grønberg, Bjørn Henning; Richardsen, Elin (Peer reviewed; Journal article, 2021)Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate ... -
Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Ottestad, Anine Larsen; Dale, Vibeke Grotnes; Richardsen, Elin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantication of nucleic acid sequences. We used absolute quantication of mutated v-Ki-ras2 Kirsten rat sarcoma viral oncogene ... -
Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer
Stokke, Kristin; Sandvei, Marie Søfteland; Grønberg, Bjørn Henning; Jordhøy, Marit Slaaen; Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien (Peer reviewed; Journal article, 2022)Background: The Glasgow prognostic score (GPS) is an established inflammatory prognostic index in cancer patients. Most studies have only measured GPS at baseline (B-GPS). Effective cancer therapy may reduce inflammation, ... -
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ... -
Thoracic Radiotherapy in Limited-Stage SCLC—a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018
Graabak, Gustav; Grønberg, Bjørn Henning; Sandvei, Marie Søfteland; Nilssen, Yngvar; Halvorsen, Tarje Onsøien (Peer reviewed; Journal article, 2022)Introduction Twice-daily (BID) thoracic radiotherapy (TRT) of 45 Gy per 30 fractions is recommended for limited-stage (LS) SCLC, but most patients are treated with once-daily (OD) schedules owing to toxicity concerns ... -
Timing of severe toxicity from chemotherapy in patients with lung cancer
Sjøgren, Kristina; Jacobsen, Kristian Aalberg; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien (Journal article; Peer reviewed, 2020)Background/Aim: The aim of this study was to investigate the timing of severe toxicity in lung cancer patients receiving chemotherapy. Patients and Methods: Patients with advanced non-small cell lung cancer or limited ... -
Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC
Killingberg, Kristin Toftaker; Grønberg, Bjørn Henning; Jordhøy, Marit Slaaen; Kirkevold, Øyvind; Halvorsen, Tarje Onsøien (Peer reviewed; Journal article, 2023)Introduction Half of the patients with limited-stage SCLC (LS SCLC) are above or equal to 70 years old, but they account for less than 20% of participants in most trials. Comorbidities and reduced organ and physical ...